Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Gains from Sales and Divestitures (2016 - 2025)

Voyager Therapeutics' Gains from Sales and Divestitures history spans 10 years, with the latest figure at $691107.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 34.12% year-over-year to $691107.0; the TTM value through Dec 2025 reached $691107.0, up 34.12%, while the annual FY2025 figure was $691107.0, 34.12% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $691107.0 at Voyager Therapeutics, up from $568331.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $691107.0 in Q4 2025 and bottomed at $184217.0 in Q1 2021.
  • The 5-year median for Gains from Sales and Divestitures is $421680.5 (2022), against an average of $416912.0.
  • The largest annual shift saw Gains from Sales and Divestitures soared 129.71% in 2021 before it dropped 13.33% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $326943.0 in 2021, then skyrocketed by 33.54% to $436611.0 in 2022, then increased by 21.75% to $531560.0 in 2023, then fell by 3.06% to $515303.0 in 2024, then skyrocketed by 34.12% to $691107.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Gains from Sales and Divestitures are $691107.0 (Q4 2025), $568331.0 (Q3 2025), and $550084.0 (Q2 2025).